This represents a potential therapeutic target for breast cancer overall, and more specifically for ER+/PR+ subtypes, which were heavily disrupted on this plate but not on any other plates containing metabolic effectors (PM-M5 to M8). This evidence concerns the gene PGR and breast carcinoma.